Chitosan-Based Nanoparticles for Twist1 Knockdown in 4T1 Cells

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Bone metastatic breast cancer significantly impacts patient quality of life and survival.
• Current treatments face limitations in effectively targeting metastatic sites.
• RNA interference (RNAi) offers a potential therapeutic avenue, but efficient delivery is crucial.

Purpose of the Study:

• To develop and evaluate chitosan-based nanoparticles (NPs) for targeted delivery of twist1-siRNA.
• To compare the efficacy of actively targeted (ALD-PEG-CHI) and passively targeted (mPEG-CHI) NPs.
• To assess the in vitro therapeutic potential of these NPs against bone-metastatic breast cancer cells.

Main Methods:

• Fabrication of alendronate-conjugated PEG-functionalized chitosan (ALD-PEG-CHI) and PEG-functionalized chitosan (mPEG-CHI) nanoparticles.
• Encapsulation of twist1-siRNA within the NPs and characterization of size, zeta potential, and serum stability.
• In vitro assessment of NP-mediated twist1 knockdown in 4T1 breast cancer cells using protein expression analysis and wound healing assays.

Main Results:

• Both ALD-PEG-CHI-siRNA and mPEG-CHI-siRNA NPs were successfully synthesized with sizes under 70 nm and near-neutral zeta potential.
• Complete encapsulation of twist1-siRNA was confirmed, with NPs providing significant serum protection (6h for ALD-PEG-CHI, 4h for mPEG-CHI).
• Demonstrated effective twist1 knockdown in 4T1 cells, inhibiting directional cell migration.

Conclusions:

• Chitosan-based nanoparticles show potential as effective delivery systems for twist1-siRNA in treating bone-metastatic breast cancer.
• Both active and passive targeting strategies utilizing these NPs are promising for therapeutic applications.
• Further in vivo studies are warranted to validate the therapeutic efficacy of these nanocarriers.